EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (OTCBB: FCSC), announced today its LAVIV order information for the second quarter ended June 30, 2012. During the second quarter of 2012, Fibrocell received orders for 387 biopsies, an increase of 104% as compared to 189 orders during the first quarter of 2012. During the second quarter of 2012, 85 new physicians placed orders for biopsies, an increase of 60% as compared to 53 new physicians during the first quarter of 2012. During the second quarter of 2012, 39 physicians placed repeat orders for biopsies, an increase of 200% as compared to 13 physicians during the first quarter of 2012. Since the launch of LAVIV in June 2011, Fibrocell has received 706 biopsy orders from 162 physicians.
